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Abstract
Background: A distinctive feature of type 2 diabetes is inability of insulin-secreting b-cells to properly respond to elevated
glucose eventually leading to b-cell failure. We have hypothesized that an abnormally increased NO production in the
pancreatic islets might be an important factor in the pathogenesis of b-cell dysfunction.
Principal Findings: We show now that islets of type 2 spontaneous diabetes in GK rats display excessive NO generation
associated with abnormal iNOS expression in insulin and glucagon cells, increased ncNOS activity, impaired glucose-
stimulated insulin release, glucagon hypersecretion, and impaired glucose-induced glucagon suppression. Pharmacological
blockade of islet NO production by the NOS inhibitor N
G-nitro-L-arginine methyl ester (L-NAME) greatly improved hormone
secretion from GK islets suggesting islet NOS activity being an important target to inactivate for amelioration of islet cell
function. The incretin hormone GLP-1, which is used in clinical practice suppressed iNOS and ncNOS expression and activity
with almost full restoration of insulin release and partial restoration of glucagon release. GLP-1 suppression of iNOS
expression was reversed by PKA inhibition but unaffected by the proteasome inhibitor MG132. Injection of glucose plus
GLP-1 in the diabetic rats showed that GLP-1 amplified the insulin response but induced a transient increase and then a
poor depression of glucagon.
Conclusion: The results suggest that abnormally increased NO production within islet cells is a significant player in the
pathogenesis of type 2 diabetes being counteracted by GLP-1 through PKA-dependent, nonproteasomal mechanisms.
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Introduction
Diabetes type 2 is now a global health problem, characterized of
both insulin resistance and impaired insulin response to glucose,
defects that are regarded multifactorial in origin and are
considered a result of both environmental and undefined genetic
factors. We have shown [1,2,3,4,5,6,7,8] that islet nitric oxide
(NO) derived from neuronal constitutive NO synthase (ncNOS) is
a strong negative modulator of glucose-stimulated insulin release.
This enzyme resides abundantly in b-cells [9]. Moreover, ncNOS
is in part associated with insulin granules [10] making it a suitable
regulator of the secretory process. We have also found, in healthy
animals, that exposure of islets to high concentrations of glucose or
lipids induces expression and strong activity of inducible NOS
(iNOS) in their b-cells concomitant with reduced insulin response
to glucose [2,3,7,11]. These data suggested to us that glucose-
induced ‘‘glucotoxicity’’ as well as lipid-induced ‘‘lipotoxicity’’ in
the b-cell, at least in part, might be due to possible nonimmuno-
genic deleterious effects of iNOS-derived NO. Hence there is
reason to believe that a sustained elevation of islet iNOS activity
and the ensuing excessive production of NO might be of
significant importance in the development of type 2 diabetes.
Nutrient ingestion stimulates secretion of gut hormones such as
glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide
(GIP), which serve to amplify glucose-stimulated insulin release
[12,13]. GLP-1 is also known to decrease glucagon release [12,13].
Both effects are glucose-dependent and GLP-1 is considered
therapeutically useful to reduce elevated blood glucose [12,13].
Therefore, GLP-1 has received great attention as treatment for type
2 diabetes [12,13,14]. We found recently that GLP-1 restored the
impairment of glucose-stimulated insulin release in islets taken from
lipid-infused rats and that this effect was linked to increased cyclic
AMP levels and suppression of islet activities of both ncNOS and
iNOS [3]. Since surprisingly even short-time (,60 min) exposure of
islets to high glucose in healthy animals was associated with
enhanced production of iNOS-derived NO [7,11], the present
investigation was undertaken to study islet NOS activities and the
influence of GLP-1 on an animal model of spontaneous type 2
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(GK) rat, which is considered a good model of human type 2
nonobese diabetes [15,16,17,18]. Because the glucagon-producing
a-cells harbor the ncNOS enzyme [9], which apparently is an
important regulator of glucagon release [1,2,3,4,6,18,19,20,21], and
because raised plasma levels of glucagon is a common feature of and
contribute to human type 2 diabetes [22] we also performed parallel
studies on glucagon secretion.
Results
Confocal microscopy of iNOS expression in islets directly
isolated from GK rats
To investigate whether isolated islets express iNOS protein we
performed a confocal microscopic study in GK islets. Islets were
simultaneously immunolabeled for insulin or glucagon to investi-
gate b- and a-cell specific expression of iNOS. As shown in
Fig. 1a, immunoreactivity for iNOS was detected in insulin
immunoreactive b-cells (A–C) and in glucagon immunoreactive a-
cells (D–F) (orange-yellowish fluorescence in the overlay pictures).
No iNOS immunoreactivity was found in Wistar control islets
(Fig. 1b). Insulin immunoreactive b-cells (G–I) and glucagons
immunoreactive a-cells (J–L) are shown.
NOS activities in islets directly isolated from GK and
Wistar rats
Fig. 1c shows that islets isolated from GK rats displayed
increased ncNOS activity. Moreover, while iNOS activity in
Wistar islets was negligible, GK islets displayed high iNOS
activity. Hence total NO generation was impressively increased in
GK compared with Wistar islets (Fig. 1c).
Effect of the NOS inhibitor L-NAME on insulin and
glucagon secretion from isolated Wistar and GK islets at
low and high glucose and in vivo effect of L-arginine
To directly study the basic involvement and regulatory role of islet
NO production for insulin and glucagon release we incubated
isolatedislets fromGKand Wistarrats at low andhigh glucoseinthe
absence and presence of the NOS inhibitor L-NAME (5 mmol/l).
Table 1a shows that glucose-stimulated insulin release from both
GK and Wistar islets is markedly amplified in the presence of L-
NAME. This amplification is more pronounced in GK islets (90%)
compared with Wistar islets (38%). No effect of L-NAME on insulin
release was seen at low glucose (Table 1a). Moreover, NOS
inhibition by L-NAME greatly suppressed the glucagon hypersecre-
tion from GK islets incubated at low glucose (Table 1b). Such an
inhibition of glucagon release from GK islets in the presence of L-
NAME could also be seen at high glucose. Further, L-NAME did
decrease glucagon secretion also from Wistar islets at low glucose,
but had no significant effect at high glucose (Table 1b). Finally, to
further test a regulatory role of ncNOS for a stimulated acute release
ofinsulinand glucagoninvivowe injectedL-arginine,whichisknown
to stimulate both insulin and glucagon secretion, in the absence and
presence of L-NAME pretreatment. Table 1c and d shows that
NOS inhibition amplified the insulin but decreased the glucagon
response following L-arginine injection in both GK and Wistar rats..
Influence of GLP-1 on basal insulin and glucagon release
in relation to islet ncNOS and iNOS expression and
activities in incubated islets from GK and Wistar rats
Since not only pharmacological blockade [5,6,8,10,11] but also
cyclic AMP stimulating agents are known to suppress islet NO
production in healthy animals[3,7], we tested possible beneficial
effects of GLP-1 on islet NOS activities in the GK rat. Fig. 2 a, b
and Table 2a show the effect of GLP-1 on islet NOS activities
and protein expression (Western blot) as well as insulin and
glucagon secretion in islets from GK and Wistar rats incubated at
low glucose (3.3 mmol/l). We used a concentration of 100 nmol/l
of GLP-1, having maximal stimulating effect on glucose-induced
insulin release in isolated rat islets [3]. Total NO generation was
markedly increased in GK islets (Fig. 2a). This was mainly due to
iNOS activity. No significant iNOS expression and activity was
detectable in Wistar islets (Fig. 2a, b). ncNOS activity was
modestly upregulated in GK islets (Fig. 2a). GLP-1 induced
pronounced suppression of iNOS expression and activity in GK
islets and suppressed ncNOS activity in both types of islets
(Fig. 2a, b and Table 2a). Basal insulin secretion in GK and
Wistar islets was similar at low glucose and GLP-1 had no effect
(Fig. 2a). Glucagon secretion was impressively increased in GK
islets vs Wistar islets (33.262.4 pg/islet per h vs 19.861.7 pg/islet
per h; p,0.01) (Fig. 2a). GLP-1 suppressed glucagon secretion to
17.261.3 pg/islet per h in GK islets and to 12.861.1 pg/islet per
h in Wistar controls. Notably, GK islets still hypersecreted
glucagon after GLP-1 treatment (Fig. 2b). The densitometric
analysis showed that GLP-1 induced a pronounced suppression of
both ncNOS and iNOS expression in GK islets. A marked
suppression of ncNOS expression was found also in Wistar islets,
while no iNOS expression could be detected (Table 2a).
Confocal microscopic study of the effects of GLP-1, the
PKA inhibitor H-89 and the proteasome inhibitor MG 132
on iNOS expression in GK islets incubated at low glucose
The suppressive effect by GLP-1 on iNOS protein expression in
islets from healthy rats incubated at high glucose is PKA-mediated
[7]. Because iNOS expression was present already in directly
isolated GK islets next experiments were conducted at low glucose
to avoid interference with in vitro glucose-induced iNOS stimula-
tion [7]. Thus immunolabeling of iNOS expression at 3.3 mmol/l
glucose was performed and effects of GLP-1 and the PKA
inhibitor H-89 were recorded. GK islets were simultaneously
immunolabeled for insulin to identify b-cell specific iNOS
expression. As shown in Fig. 3 A–C, iNOS immunoreactivity
was detected in insulin-immunoreactive b-cells. GLP-1
(100 nmol/l) greatly suppressed the expression of iNOS (Fig. 3
D–F) and the PKA inhibitor H-89 (2 mmol/l) reversed this
suppression (Fig. 3 G–I). Fig. 3 J–L shows that H-89 by its own
has no apparent effect on iNOS expression. Finally we studied the
possible involvement of the proteasome system, since the
proteasome has been suggested to modulate iNOS expression in
other cell types [23,24]. Fig. 3 M–O shows that the suppressive
effect of GLP-1 on iNOS expression (Fig. 3 D–F) was not reversed
by the proteasome inhibitor MG 132 (10 mmol/l), and Fig 3 P–R
shows, surprisingly, that the prominent iNOS expression in the b-
cells (Fig. 3 A–C) was abolished also after incubation with MG
132 itself. Fig. 3 S–U shows that no iNOS expression was found in
Wistar control islets.
Influence of GLP-1 on insulin and glucagon release in
relation to islet ncNOS and iNOS expression and activities
in islets from GK and Wistar rats incubated at high
glucose
Fig. 4a, b and Table 2b shows the effect of GLP-1 on NOS
activities and protein expression in islets incubated at high glucose
(16.7 mmol/l). Again, NOS activities were increased in GK
compared with Wistar islets. This was mainly due to increased
iNOS activity (Fig. 4a). However, upregulation of NOS activities
Islet NO Generation and GLP-1
PLoS ONE | www.plosone.org 2 May 2008 | Volume 3 | Issue 5 | e2165Figure 1. a Confocal microscopy of islets directly isolated ex vivo from the GK rat. The islets were double-immunolabelled for insulin or glucagon
and iNOS and analysed by confocal microscopy. Insulin staining and iNOS staining appear, respectively, as red (A) and green (B) fluorescence. Co-
localization of insulin/iNOS is seen as orange-yellowish fluorescence (C). Similarly glucagon staining and iNOS staining appear, respectively, as red (D)
and green (E) fluorescence. Co-localization of glucagon/iNOS is seen as orange-yellowish fluorescence (F). Bars indicate lengths (10 mm). b Plates G–I
and J–L show the absence of iNOS fluorescence in Wistar control islets (H, K). c NOS activities in freshly isolated islets. NO production from ncNOS,
iNOS and total NOS in freshly isolated islets from Wistar control rats (open bars) and GK rats (hatched bars). Values are mean6s.e.m for n=4–6
animals. *P,0.05; *** P,0.001
doi:10.1371/journal.pone.0002165.g001
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glucose possibly because NOS activities were already upregulated
in vivo and in comparison high glucose increased NOS activities
also in Wistar islets (Fig. 4a, b). NO production and Western
blots show that GLP-1 reduced both expression and activities of
iNOS and ncNOS (Fig. 4a, b, Table 2b). This suppression was
associated with a prominent increase in glucose-stimulated insulin
release and thus the impairment of glucose-induced insulin
response in GK islets was efficiently counteracted (Fig. 4a).
Moreover, while high glucose suppressed glucagon secretion in
Wistar islets, negligible suppression by glucose was found in
glucagon hypersecreting GK islets (compare Fig. 2a and 4a).
GLP-1 reduced glucagon secretion in both types of islets (Fig. 2a).
However, compared to Wistar, GK islets still displayed elevated
glucagon secretion even after combination of high glucose and
GLP-1 (Fig. 4a). The densitometric analysis showed that GLP-1
induced a marked suppression of both ncNOS and iNOS
expression in GK as well as Wistar islets (Table 2b).
Basal plasma levels of insulin, glucagon and glucose in
GK and Wistar rats and effects of glucose and GLP-1
injections
Since GK islets apparently hypersecreted glucagon we measured
circulating levels of glucagon, insulin and glucose in vivo. In addition
we measured islet content of glucagon and insulin. Plasma levels of
glucagon and glucose were elevated in GK rats, while insulin levels
were not appreciably different. However, calculating the basal
insulinogenic index, i.e. dividing circulating insulin concentrations
with circulating glucose concentrations, revealed that the insulin
response to basal glucose was impaired in GK vs Wistar rats (data not
shown). The plasma levels were as follows, Wistar vs GK: Insulin
(pmol/l) 10068 vs 8166.4 (NS); Glucagon (ng/l) 254.5610.2 vs
311.5612.9 (p,0.001); Glucose (mmol/l) 7.360.2 vs 11.060.2
(p,0.001). There were 28 animals in each group. Islet content of
insulin and glucagon at 6 weeks of age was similar in GK and Wistar
rats. Insulin content Wistar vs GK was 5.560.6 and 5.660.9 nmol/
mg protein and glucagon content 1.0260.09 and 0.8960.09 mg/mg
protein (n=8 in each group). Because the action of GLP-1 is known
to be highly glucose-dependent [12,13] we examined in vivo insulin
and glucagon responses to GLP-1 mixed with glucose. Fig. 5a–b
shows the effects of an iv injection of this mixture and a control
experiment with a high dose of glucose alone (Fig. 5d–e).Theinsulin
response to the combination of GLP-1 and glucose was modestly
lower in GK compared with Wistar. However, there was an
abnormal transient increase in glucagon response followed by a slow
suppression, which did not reach the low levels of glucagon recorded
in Wistar. After injection of glucose alone the insulin response in GK
rats was abrogated, and the glucagon response showed an initial
normal suppression but a marked rebound (Fig. 5d–e). An impaired
glucosetolerance curve after glucose alone (Fig. 5f) was still impaired
in the GK rat even after addition of GLP-1 (Fig. 5c).
Discussion
Previous studies have suggested that high amounts of NO derived
fromiNOSactivity arecytotoxicandimplicated inthe autoimmune-
mediated dysfunction and destruction of islet b-cells during
development of type 1 diabetes [25]. This iNOS-stimulated NO
production is not only mediated by invading macrophages but also
by the b-cells themselves [25]. On the other hand, the role of islet
ncNOS, which produces small amounts of NO in a signaling way, is
still unclear [1,2,3,4,5,6,7,8,10,11,18,19,20,26,27,28,29,30]. We
have found that inhibition of ncNOS activity is accompanied by
increased insulin release induced by glucose, L-arginine and to a
lesser extent by cholinergic stimulation, while secretion induced by
agents directly stimulating the cyclic AMP system is not inhibited
and might even be slightly increased by NO [1,2,3,4,5,6,7,8,11,
19,20,29].Moreover,islet NOS activitiesare efficientlycounteracted
by the cyclic AMP/PKA system [2,3,7,29].
Based on these observations we proposed that ncNOS-derived
NO might serve as a physiological negative feedback inhibitor of
acute glucose-stimulated insulin release [1,3,5,7,8,11]. Further-
more, we have shown in healthy mice that hyperglycemia lasting
for only ,60 min results in islet iNOS expression and activity
[11], a finding that raised the question whether the islet NO
system, and especially iNOS, might be implicated also in the
development of nonimmunogenic type 2 diabetes.
Our present results showed a rich occurrence of iNOS protein in
both b-cellsanda-cellsofisletsisolatedfromthediabeticGKrat.The
abundance of iNOS expression in the a-cells of the GK rat was
unexpected, since injection of large doses of iNOS-stimulating
endotoxin did induce iNOS only in single a-cells while almost all b-
cells were affected [9,29]. This observation thus raised the question
whether long-term hyperglycemia might contribute to nonimmuno-
genic diabetes by inducing iNOS in the a-cells. Because NO not only
inhibits insulin release but also stimulates glucagon release
[1,2,3,6,19,20,21,29] this observation thus underlined a possible
pathogenic role of the islet NO system in the development of type 2
diabetes. In accordance, GK islets displayed increased ncNOS
activity and impressive iNOS activity compared with Wistar control
islets. These findings might, at least in part, explain the defective
Table 1. Effect of the NOS inhibitor L-NAME on insulin and
glucagon release in vitro and in vivo.
Wistar GK
Insulin release (ng/islet per h)
a) 1G 0.26960.029 0.25860.032
1G+L-NAME 0.30560.052 0.30360.033
16.7G 4.0160.32 1.8960.26
16.7G+L-NAME 5.6160.35 ** 3.6860.38 ***
Glucagon release (pg/islet per h)
b) 1G 29.4661.1 41.0461.62
1G+L-NAME 20.0461.3 ** 29.3861.7 **
16.7G 18.3361.9 36.6462.25
16.7G+L-NAME 15.6762.1 26.3562.53 **
Plasma insulin response (pmol/l)
c) Saline+L-arg. 9486111 238654
L-NAME+L-arg. 1349682 ** 410652 *
Plasma glucagon response (ng/l)
d) Saline+L-arg. 551645 404671
L-NAME+L-arg. 331667 * 214636 *
Effect of pharmacological blockade of islet NO generation by the NOS inhibitor
L-NAME on islet hormone secretion from Wistar and GK rats. a) Insulin release
and b) glucagon release from isolated islets at low and high glucose in the
absence or presence of L-NAME (5 mmol/l). n=8 in each group. Asterisks
denote significant effects of L-NAME at 1G or 16.7G.
*p,0.05;**p,0.01;***p,0.001.
c) Peak insulin response and d) Peak glucagon response in plasma at 2 min
after an i.v. injection of L-arginine (L-arg.) (3.6 mmol/kg) following pretreatment
with saline or L-NAME (1.2 mmol/kg). There were 4–7 animals in each group.
Asterisks denote significant effects of L-NAME pretreatment.
*p,0.05;**p,0.01
doi:10.1371/journal.pone.0002165.t001
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rats and also a possible deleterious effect of iNOS-derived NO on the
b-cells over time. Further, the present data showing an abnormally
increased iNOS-derived NO production also after in vitro incubation
of GK islets at low glucose suggest that moving the islets from an in
vivo hyperglycemic milieu to a medium of a low ‘‘hypoglycemic’’
glucose concentration (3.3 mmol/l) for a period of ,2hd i dn o t
reduce or abolish iNOS expression and activity.
The NOS inhibitor L-NAME has previously been shown to
serve as a potent inhibitor of islet ncNOS activity both in vitro and
in vivo in the rat as well as in the mouse [5,6,8,10,11,19,27,31].
Such a pharmacological inhibition of b-cell ncNOS activity was
now found to restore the impaired insulin response to glucose and
also to restore, at least in part, the increase glucagons secretion in
GK islets thus suggesting that the increased NO generation in
these islets is indeed an important factor for b-cell dysfunction and
a-cell hyper-responsiveness in this model of animal type 2
diabetes. These results were further strengthened by the in vivo
L-arginine data showing that L-NAME amplified the insulin but
decreased the glucagon response. This is in accordance with a
recent study in a new rat model of type 2 diabetes induced by
streptozotocin- nicotinamide [32]. These authors found that an
impaired ncNOS expression was associated with insulin release
hyper-responsiveness to L-arginine.
Figure 2. (a) NOS activities and hormone secretion in islets incubated at low glucose. Islet NO production from ncNOS, iNOS and total NOS as well as
insulin and glucagon release from islets of Wistar or GK rats incubated at 3.3 mmol/l glucose in the absence (open bars) and presence (dark bars) of
100 nmol/l GLP-1. Values are mean6s.e.m for 5–9 batches of islets at each point. *P,0.05; ** P,0.01; *** P,0.001. (b) Representative examples of
Western blots of iNOS and ncNOS protein in the absence and presence of GLP-1 are shown.
doi:10.1371/journal.pone.0002165.g002
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protective mechanism against the NO-mediated negative effects
on b-cell function in GK rats might be exerted through the cyclic
AMP system. We therefore selected the potent cyclic AMP-
generating incretin, GLP-1 as a suitable agent to test this
hypothesis. In our present short-term experiments GLP-1
counteracted the impaired insulin response to glucose and induced
a marked decrease in islet NOS activities. Since we have shown
that increased islet endogenous NO production and addition of
exogenous NO gas or an intracellular NO donor to incubated
islets are accompanied by reduction of glucose-stimulated insulin
response [1,2,3,5,8,11], we are now inclined to ascribe, at least in
part, the beneficial effect of GLP-1 on the impairment of acute
glucose-induced insulin release in the GK rat to its suppressive
action on the islet NO system. Apart from its effect on the cyclic
GMP system, NO is known to affect multiple targets within the
cell, mainly acting through S-nitrosylation [33,34,35,36]. It is
unclear whether cyclic GMP, the glutathione system and/or
different regulatory proteins in the stimulus-secretion coupling are
primarily affected [8,11,34,35,36,37] and regulation of NOS
activities has been observed at all levels from gene transcription to
covalent modification and allosteric regulation of the enzyme itself
[33]. Interestingly, recent results from brain tissue have demon-
strated that a number of metabolic, structural, and signaling
proteins might be afflicted by NO through S-nitrosylation
processes [36]. Notably the present study was performed in very
young GK rats, and thus a more or less continuous activity of
iNOS-derived NO might have further deleterious effects on the b-
cell in the long run and earlier studies showed that b-cell numbers
were diminished in 6-months old GK rats [15]. Such a notion is
further underlined by previous data showing marked diabetes in
mice with iNOS overexpression in their b-cells [38]. It should be
recalled that the b-cell mass in the Stockholm GK colony is not
affected in young rats [39].
The possible implication of proteasomal mechanisms in the loss
of iNOS protein during short-time islet incubation with GLP-1
was explored by using the proteasome inhibitor MG 132.
Unexpectedly, MG 132 did not reverse the GLP-1-induced
suppression of iNOS expression but instead induced loss of iNOS
protein and hence proteasomal inhibition did not prevent but
stimulated degradation of iNOS, suggesting other control
mechanisms regulating the cellular balance of this protein. A
similar paradoxical effect of proteasomal inhibition was reported
concerning (pro)insulin, the degradation of which was increased by
the proteasome inhibitor lactacystin [40]. Similarly, b-cell iNOS
induced by lipid infusion to rats was abolished by treatment of
isolated islets from such rats with MG 132 [41]. A paradoxical
effect of proteasomal inhibition by MG 132 was also reported in
Table 2. Densitomeric analysis of iNOS and ncNOS protein
expression.
Wistar GK
a) 3.3G 3.3G+GLP-1 3.3G 3.3G+GLP-1
iNOS 0.260.09 0.1360.05 18.763.3 8.561.1 ***
ncNOS 15.561.5 10.161.2 * 22.963.1 7.662.3 ***
b) 16.7G 16.7G+GLP-1 16.7G 16.7G+GLP-1
iNOS 16.362.05 6.160.91 *** 24.562.8 10.462.9 ***
ncNOS 25.262.4 15.0561.7 ** 40.564.1 11.362.01 ***
Densitometric analysis of Western blots for iNOS and ncNOS expression after
incubation of Wistar and GK islets in the absence and presence of GLP-1
(100 nmol/l) at a) low glucose, 3.3 mmol/l (3.3G) and b) high glucose,
16.7 mmol/l (16.7 G). Asterisks denote significant effect of GLP-1 for n=4 in
each group.
*p,0.05;***p,0.001.
doi:10.1371/journal.pone.0002165.t002
Figure 3. Confocal microscopy of incubated islets from the GK
rat. Isolated islets were incubated for 90 min in the presence of; A, B
and C) 3.3 mmol/l glucose; D, E and F) 3.3 mmol/l glucose+100 nmol/l
GLP-1; G, H and I) 3.3 mmol/l glucose+100 nmol/l GLP-1+2 mmol/l H-
89; J, K and L) 3.3 mmol/l glucose+2 mmol/l H-89; M, N and O)
3.3 mmol/l glucose+100 nmol/l GLP-1+10 mmol/l MG 132; P, Q and R)
3.3 mmol/l glucose+10 mmol/l MG 132. After incubation the islets were
double immunolabeled for insulin and iNOS and analysed by confocal
microscopy. Insulin and iNOS stainings appear, respectively, as red (A,
D, G, J, M and P) and green (B, E, H, K, N and Q) fluorescence. Co-
localisation of insulin/iNOS is seen as a orange-yellowish fluorescence (C,
F, I, L, O and R). Plates S-U shows Wistar control islets at 3.3 mmol/l
glucose. No iNOS expression could be detected (T). Bars indicate
lengths (10 mm).
doi:10.1371/journal.pone.0002165.g003
Islet NO Generation and GLP-1
PLoS ONE | www.plosone.org 6 May 2008 | Volume 3 | Issue 5 | e2165vascular smooth muscle [23]. These observations raised the
question whether certain regulatory mechanisms modulating the
expression and degradation of iNOS might be circumvented by
the lack of appropriate signaling through the mere presence of a
proteasome inhibitor or by other less well-understood mechanisms
possibly including factors affiliated with ER stress [42,43]. In fact,
very recent studies have shown a most complex series of events
induced by various proteasomal inhibitors in different
tissues[44,45]. Thus proteasome inhibition indeed seems to induce
ER stress followed by activation of autophagic processes in e.g. b-
cells [44], embryonic fibroblasts and different cancer cell lines
[45], while HEK 293 cells and macrophage cell line RAW 264.7
were dependent on the proteasome degradation pathway [24].
The present observation that proteasome inhibition in GK b-cells
stimulates the degradation of iNOS protein within 90 min raises
further questions concerning the complex interaction between the
Figure 4. (a) NOS activities and hormone secretion in islets incubated at high glucose. Islet NO-production from ncNOS, iNOS and total NOS as well
as insulin and glucagon release from islets of Wistar or GK rats incubated at 16.7 mmol/l glucose in the absence (open bars) and presence (dark bars)
of 100 nmol/l GLP-1. Values are mean6s.e.m for 6–10 batches of islets at each point. *P,0.05; ** P,0.01; *** P,0.001. (b) Representative examples
of Western blots of iNOS and ncNOS protein in the absence and presence of GLP-1 are shown.
doi:10.1371/journal.pone.0002165.g004
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will be answered in future studies.
Our in vivo experiments showed that a combination of GLP-1
and glucose induced a fairly good insulin response in GK rats,
while the response to glucose alone was abrogated. These results
agreed with our in vitro data, showing a restraining action of GLP-1
on islet NOS activities, and a concomitant amplification of
glucose-stimulated insulin release. These effects of GLP-1 are most
likely attributed to its ability to increase the islet cyclic AMP/PKA
system as previously suggested from our data in healthy animals
[2,3,7]. Although also PKA-independent effects of cyclic AMP on
distal steps in the stimulus-secretion coupling are described [46]
our data favor PKA being of major importance for the regulation
of islet NOS activities.
The basal plasma concentrations of glucagon in young GK rats
were increased. Moreover, an abnormal secretion of glucagon in
GK rats was detected after injecting GLP-1 plus glucose. An
unexpected transient hypersecretory glucagon response was
followed by a slight suppression, which was less pronounced
compared with the marked decrease of glucagon observed in
controls. Hence GLP-1 only in part restored the abnormal
hypersecretion of glucagon in GK rats. Glucose alone, however,
induced a normal initial transient fall of glucagon but this eas
followed by a marked rebound at 60 min. An abnormal
hypersecretion of glucagon from GK islets was also observed in
vitro. Notably glucose had a negligible suppressive effect on
glucagon secretion in isolated GK islets, while GLP-1 decreased
glucagon release concomitant with decreased NO generation in
both types of islets, although less efficient so in GK islets. These
data thus suggest that GLP-1 has a good amplifying effect on
glucose-stimulated insulin release but might be less efficient in
strengthening glucose-induced glucagon suppression in vivo in this
model of type 2 diabetes. NO is an important stimulator of
glucagon secretion in healthy animals [1,2,3,6,19,20,21,29,47] and
ncNOS resides in both b-cells and a-cells [9], while no expression
of iNOS is observed. As mentioned above, in GK rats there is an
abundance of peripherally located islet cells, which were iNOS
positive and corresponded to glucagon cells showing, that iNOS
indeed is highly expressed also in the a-cells of the diabetic rats.
Increased levels of circulating glucagon are a common feature in
human type 2 diabetes [22]. Hence the present data strongly
suggest that an abnormally increased NO production in a-cells
Figure 5. In vivo action of GLP-1 and glucose. Effect of an iv injection of GLP-1 (10 nmol/kg)+glucose (4.4 mmol/kg)(a–c) or glucose alone
(11.1 mmol/kg)(d–f) on the plasma concentrations of insulin, glucagon and glucose in Wistar and GK rats. Values are mean6s.e.m for 8 animals in
each group. *P,0.05; ** P,0.01; *** P,0.001.
doi:10.1371/journal.pone.0002165.g005
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diabetes. The mechanisms of a less efficient effect by GLP-1 to
suppress glucagon secretion in diabetes remain unclear but further
underline the importance of restoring glucagon hypersecretion in
this disease.
In conclusion, we believe that the importance of deleterious
effects of excessive islet NO production in nonimmunogenic type 2
diabetes has been seriously overlooked and might explain some if
not all of the impairments of islet hormone secretion and b-cell
survival. The present data show that abnormally increased
expression and activities of islet NOS isoenzymes coincide with
increased glucagon secretion and decreased glucose-stimulated
insulin release and thus that an excessive NO production is an
important contributing factor for the diabetic condition. GLP-1
can, only in part, counteract these abnormalities through
activating the cyclic AMP/PKA system. Our data also suggest
that high concentrations of circulating glucagon is important for
the diabetic condition even in the presence of GLP-1, although
this incretin hormone contributes to an increased insulin release
through suppressing the NOS activities in the b-cell. These novel
data on an NO-generated glucotoxic action in GK islets might be
applicable, at least in part, to human type 2 diabetes and hopefully
pave the way for new therapeutic interventions to reduce islet NO
production.
Materials and Methods
Animals
Young age-matched male GK rats of the Stockholm colony
bred at the Karolinska Institute and Wistar control rats
(commercially available from B&K, Sollentuna, Sweden) 5–
7 weeks old were used in all experiments. They were fed a
standard pellet diet (B&K) and tap water ad libitum. Notably it is
known that certain colonies of Wistar rats might have a defective
insulin response to glucose. Ancillary experiments in our
laboratory, however, have shown that the actual B&K Wistar rats
display an insulin response comparable to that of age-matched
Sprague-Dawley rats. The experiments were approved by the
Ethical Committee for Animal Research at the University of Lund,
Sweden.
Chemicals
Bovine serum albumin was from ICN Biochemicals, High
Wycombe, UK. Glucagon-Like Peptide-1 (7–36) amide (GLP-1)
was from Peninsula Laboratorie s ,B e l m o n t ,C A ,U S A .H - 8 9a n d
MG 132 were from Calbiochem, La Jolla, CA, USA. The NOS
inhibitor N
G-nitro-L-arginine methyl ester hydrochloride (L-
NAME) and all other drugs and chemicals were from Sigma
Chemicals, St Louis, MO, USA or Merck AG, Darmstadt,
Germany. Polyclonal rabbit anti-iNOS and HRP-conjugated
goat anti-rabbit IgG was from StressGen Biotechnologies Corp,
Victoria, BC, Canada. Cy2-conjugated anti-rabbit IgG and
Cy5-conjugated anti-guinea pig IgG were from Jackson
Immunoresearch Laboratories Inc, West Grove, PA, USA.
The radioimmunoassay kits for insulin and glucagon determi-
nations were obtained from Diagnostika (Falkenberg, Sweden)
and Eurodiagnostica (Malmo ¨, Sweden), respectively.
Isolation of pancreatic islets
Preparation of isolated pancreatic islets was performed by
retrograde injection of a collagenase solution via the bile-
pancreatic duct as previously described [1]. Islets were then
collected under a stereomicroscope at room temperature.
In vitro experiments
The freshly isolated islets were preincubated for 30 min at 37uC
in Krebs Ringer bicarbonate (KRB) buffer, pH 7.4, supplemented
with 10 mmol/l HEPES, 0.1% bovine serum albumin, and
3.3 mmol/l glucose. The composition of the KRB buffer was (in
mmol/l); NaCl 120, KCl 4.7, CaCl2 2.54, KH2PO4 1.2, Mg SO4
1.2 and NaHCO3 25. Each incubation vial contained 250 islets in
1.5 ml buffer solution (60 islets in 1.5 ml for confocal experiments)
and was gassed with 95% O2-5% CO2 to obtain constant pH and
oxygenation. After preincubation the buffer was changed to a
medium containing the test agents, and the islets were incubated
for 90 minutes. All incubations were performed at 37uCi na n
incubation box (30 cycles/min). Immediately after incubation,
aliquots of the medium were removed for assay of insulin and
glucagon [48,49,50] and the islets were prepared for measurement
of NOS activities as described below.
Immunofluorescence and confocal microscopy
Islets freshly isolated or collected after incubation in KRB buffer
as described above were fixed with 4% formaldehyde, permeabi-
lized with 5% Triton X-100, and unspecific sites blocked with 5%
Normal Donkey Serum (Jackson Immunoresearch Laboratories
Inc, West Grove, PA, USA). iNOS was detected with a rabbit-
raised polyclonal anti-iNOS antibody (StressGen Biotechnologies
Corp, Victoria, BC, Canada) (1:100) in combination with Cy2-
conjugated anti-rabbit IgG (Jackson Immunoresearch Laborato-
ries Inc, West Grove, PA, USA). (1:150). For staining of insulin
and glucagon, islets were incubated with a guinea pig-raised anti-
insulin antibody (1:1000) and anti-glucagon antibody (1:200)
(Eurodiagnostica, Malmo ¨, Sweden) followed by an incubation with
a Cy5-conjugated either anti-guinea pig IgG antibody (insulin) or
Cy5-conjugated anti-rabbit IgG antibody (glucagon) (Jackson
Immunoresearch Laboratories Inc, West Grove, PA, USA)
(1:150). The fluorescence was visualized with a Zeiss LSM510
confocal microscope by sequentially scanning at (excitation/
emission) 488/505-530 nm (Cy2) and 633/.650 nm (Cy5).
Measurement of NOS activities
Isolated islets (batches of 250 islets in 1.5 ml of buffer solution)
were either prepared for direct assay of NOS activities or
preincubated for 30 min and then incubated for 90 min in KRB
buffer as described above. Thereafter an aliquot of the medium
was taken for the assay of insulin and glucagon. Islets were
thoroughly washed and collected in ice-cold buffer (200 ml)
containing HEPES (20.0 mmol/l), EDTA (0.50 mmol/l) and D,
L-dithiothreitol (DTT) (1.0 mmol/l), pH 7.2, and stored at
220uC for subsequent NOS analysis [1,11]. In brief, after
sonication on ice, the buffer solution containing the islet
homogenate was supplemented to contain also CaCl2
(0.45 mmol/l), calmodulin (25 U/ml), NADPH (2.0 mmol/l)
and L-arginine (0.2 mmol/l) in a total volume of 450 ml for
determination of total NOS. For the assay of iNOS another
portion of the homogenate was incubated in the absence of both
calmodulin and CaCl2 [11]. The homogenates were then
incubated at 37uC under constant air bubbling (1.0 ml/min) for
180 minutes. Aliquots of the incubated medium (200 ml) were
mixed with an equal volume of o-phtaldialdehyde reagent solution
in a glass vial and then passed through an 1 ml Amprep CBA
cation-exchange column for high-performance liquid chromatog-
raphy (HPLC) analysis. The amount of L-citrulline formed (NO
and L-citrulline are produced in equimolar concentrations) was
then measured in a Hitachi F1000 fluorescence spectrophotometer
(Merck, Darmstadt, Germany) as previously described [1,11]. The
resulting activity for iNOS was subtracted from total NOS activity
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Bradford method [51].
Western blot analysis
Islets incubated as stated above for the assay of islet NOS
activities were analyzed for immunoblotting. After incubation the
islets were washed in Hanks’ buffer and then suspended in 150 ml
of 10 mmol/l Tris lysis buffer, pH 7.4, containing 0.5% Triton X-
100, 0.5 mmol/l EDTA and 0.2 mmol/l PEFA block, frozen and
sonicated on ice on the day of analysis [11]. The protein content of
the supernatant was determined according to Bradford [51].
Homogenate samples representing 10 mg of total protein were run
on 7.5% SDS-polyacrylamide gel (Bio-Rad, Hercules, CA, USA).
After electrophoresis, proteins were transferred to nitrocellulose
membranes (Bio-Rad). The membranes were blocked in LS-buffer
(10 mmol/l Tris, pH 7.4, 100 mmol/l NaCl, 0.1% Tween-20)
containing 5% non-fat dry milk powder for 40 min at 37uC.
Incubation was performed with rabbit anti-mouse ncNOS (N-
7155) and iNOS (N-7782) (1:2000; Sigma, St Louis, MO, USA).
After three washings in LS-buffer the membranes were finally
incubated with a horseradish peroxidase-conjugated goat anti-
rabbit antibody (1:50000). Immunoreactivity was detected using
an enhanced chemiluminescence reaction (Pierce, Rockford, IL,
USA). The intensities of the bands were quantified by densitom-
etry (Bio-Rad GS-710 Densitometer).
In vivo studies
The rats were injected i.v with a mixture of GLP-1 (10 nmol/kg)
and glucose (4.4 mmol/kg), or glucose alone (11.1 mmol/kg) and
blood sampling was performed as described previously [17]. GLP-
1 was dissolved in 0.9% NaCl-0.1% gelatine. In the L-arginine
experiments L-NAME (1.2 mmol/kg) or saline (controls) was
injected i.v. 10 seconds before the i.v. injection of L-arginine
(3.6 mmol/kg). Both L-NAME and L-arginine were dissolved in
0.9% NaCl. The volume load was 5 ml/g rat.
Determination of insulin, glucagon and glucose
Insulin and glucagon were determined with radioimmunoassays
[48,49,50]. Glucose was determined with glucose oxidase.
Statistics
Results are expressed as mean6s.e.m. Probability levels of
random differences were determined by the unpaired Student’s t-
test or where applicable by analysis of variance followed by Tukey-
Kramer’s multiple comparison test.
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